EXCLUSIVE: Psychedelic Treatment Platform Maya Health Raises $4.3M, Bridging Clinical & Real-World Practices' Gap

Psychedelic treatments are on the cusp of being accepted therapies for the masses. Good data will likely help drive best practices.

The field of psychedelic discovery currently exists in two distinct domains: clinical studies conducted by scientists under strict lab conditions, many pursuing FDA approval, and everything else outside of those trials. That everything else represents a massive data set that could inform clinical trials. Yet for decades much of that information has gone underutilized.

Often referred to as “real-world evidence,” non-clinical practices span personal, therapeutic and ceremonial usage. Experiences range from psychedelic retreats in places like Jamaica and Mexico to use by therapists in cities that include Denver and Oakland, where many psychoactive drugs have been decriminalized.

There is a pervasive approach outside of the lab that represents a missed opportunity: how data is collected, documented and measured in a standardized manner. Clinical labs, by their very nature, require strict protocols and documentation, while non-medical settings are typically more freeform and non-standardized.

Bridging The Gap Of Clinical and Real-World Data

Two years ago, David Champion, CEO of psychedelic treatment platform Maya Health, recognized the unique opportunity presented by the disconnect between psychedelic and real-world practices. Given the widespread acceptance of psychedelic drugs outside of clinical trials, he saw a wellspring of data in that environment that was ripe to be collected and shared with scientists conducting trials.

Investors have seen the worth behind Maya Health, too. On Friday, the company announced a successful raise of $4.3 million in …

Full story available on Benzinga.com

More EXCLUSIVE: Psychedelic Treatment Platform Maya Health Raises $4.3M, Bridging Clinical & Real-World Practices' Gap